Clinical Trials Register
Print   |  A  |  A
   

The table presented below describes the list of clinical trials open for patient participation at Victorian hospitals who are members of CTA. This is updated on a monthly basis.

CTA recommends that you contact your own doctor in regard to any of these listed trials, who can then contact the Victorian institution nominated.

For non-CTA studies please refer to the Victorian Cancer Trials Link (VCTL) 

View cancer trials for with Pre Screening Protocol
Cancer typeTitle/descriptionPre Screening ProtocolParticipating members
Haematology

A Phase 1b, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Assess Safety, Tolerability and Antitumor Activities of the Combination of BGB-3111 with BGB-A317 in Subjects with B-Cell Lymphoid Malignancies. BGB-3111_BGB-A317_Study_001 - CT798

NoPeter MacCallum Cancer Centre
Breast

GO29689: A phase II, open-label, randomized study of GDC-0810 versus fulvestrant in postmenopausal women with advanced or metastatic ER+/HER2-Breast cancer resistant to aromatase inhibitor therapy. CT793

NoWestern Health
Gastrointestinal

2012-PT023: Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer.  CT797

NoA/Prof Peter Gibbs
Other

A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma. I5B-MC-JGDL - CT799

NoPeter MacCallum Cancer Centre
Melanoma

Checkmate 511: Phase IIIb/IV, Randomized, Double Blinded, Study of Nivolumab 3 mg/kg in Combination with Ipilimumab 1 mg/kg vs Nivolumab 1 mg/kg in Combination with Ipilimumab 3 mg/kg in Subjects with Previously Untreated, Unresectable or Metastatic Melanoma. CA209-511 - CT826

NoAlfred Health
Haematology

IMG-CTP-001: A study of minimal residual disease (MRD) after standard-of-care induction in patients with acute myeloid leukaemia (AML).  Genomics - NC124

NoPeter MacCallum Cancer Centre
Other

A4091061: A phase 3, randomized, double-blind, placebo-controlled, multicenter study of the analgesic efficacy and safety of the subcutaneous administration of tanezumab (PF-04383119) in subjects with cancer pain predominantly due to bone metastasis receiving background opioid therapy. CT804

NoMonash Health
Gastrointestinal

KEYNOTE-177: A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma. 177-00 - CT788

NoWestern Health
Other

Eagle: A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy and MEDI4736 in Combination with Tremelimumab Versus Standard of Care Therapy in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck(SCCHN). D4193C00002 - CT765

NoAlfred Health
Breast

A study of palbociclib in combination with letrozole as treatment of post-menopausal women with hormone receptor-positive, HER2-negative advanced breast cancer for whom letrozole therapy is deemed appropriate. A5481037 - CT810

NoMonash Health; Western Health; Peter MacCallum Cancer Centre
Haematology

Hercules: A Phase III Double-Blind, Randomized, Parallel Group, Multicenter Placebo-Controlled Trial to Study the Efficacy and Safety of Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura. ALX0681-C301 - CT802

NoRoyal Melbourne Hospital
Melanoma

TACTI-mel IMP321-P012: A multicentre, open label, dose escalation, Phase 1 study in patients with unresectable or metastatic melanoma receiving IMP321 (LAG-3Ig fusion protein) as an adjunctive therapy to anti-PD-1 therapy with pembrolizumab. CT807

NoAlfred Health
Haematology

20150161: A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects With Relapsed or Refractory Multiple Myeloma. CT803

NoRoyal Melbourne Hospital
Gastrointestinal

BNC101.001: A Phase I, Dose Escalation Study of BNC101 (anti-LGR5 humanized monoclonal antibody) in patients with metastatic colorectal cancers. CT809

NoRoyal Melbourne Hospital
Gastrointestinal

Evaluation of temporal dynamics of RAS Mutation emergence in Cell Free DNA (cfCNA)in response to first-line cetuximub anti-EGRF therapy to inform and monitor resistance in Patients with Metastatic Colorectal Cancer. WEHI-ctDNA-06 - NC113

NoRoyal Melbourne Hospital, Western Health
Haematology

AG-221-AML-004 -Idhentify: A phase 3, multicenter, open-label, randomized study comparing the efficacy and safety of AG-221 (CC-90007) versus conventional care regimens in older subjects with late stage acute myeloid leukemia harboring an isocitrate dehydrogenase 2 mutation - CT795

NoPeter MacCallum Cancer Centre
Melanoma

Checkmate 401: Clinical Trial of Nivolumab (BMS-936558) Combined with Ipilimumab Followed by Nivolumab Monotherapy as First-Line Therapy of Subjects with Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma. CA209401

NoCabrini Health
Other

CA017003: A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab (BMS-936558, anti-PD-1 Monoclonal Antibody) in Advanced Malignant Tumors. CT789

NoRoyal Melbourne Hospital
Haematology

MicroLen: Micro-dose lenalidomide as maintenance therapy post-allogeneic haematopoietic cell transplantation for patients with acute myeloid leukaemia or myelodysplastic syndromes, at high risk of relapse.

NoRoyal Melbourne Hospital
Lung

HM-EMSI-202 - ELUXA-1: A single-arm, open-label, Phase 2 study evaluating the efficacy, safety and pharmacokinetics of HM61713 in patients with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI). CT776

NoWestern Health
Lung

SOLAR: An Open-label, Randomized Phase 3 Efficacy Study of ASP8273 vs Erlotinib or Gefitinib in First-line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer Tumors with EGFR Activating Mutations. 8273-CL-0302 - CT778

NoWestern Health
Other

KEYNOTE 158: A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors. MK-3475-158 - Basket Keytruda-158 - CT806

NoPeter MacCallum Cancer Centre
Lung

B9991005: A phase 1B/2, open label, dose-finding study to evaluate safety, efficacy, pharmacokinetics and pharmacodynamics of avelumab (MSB0010718C) in combination with either crizotinib or PF-06463922 in patients with advanced or metastatic non-small cell lung cancer.  CT781

NoPeter MacCallum Cancer Centre
Haematology

PCI-32765CAN3001: A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study. CT796

NoPeter MacCallum Cancer Centre
Lung

D5160C00022 - Astris: Open label, multinational, multicenter, real work treatment study of single agent AZD9291 for patients with advanced/metastatic epidermal growth factor receptor (EGFR) T790M mutation-postitive non-small cell lung cancer (NSCLC) who have received prior therapy with an EGFR tyrosine kinase inhibitor (EGFR-TKI). CT786

NoPeter MacCallum Cancer Centre
Phase 1

CMD-2015-001: A Phase 1 Dose-Finding and Pharmacokinetic Study of DpC, Administered Orally to Patients with Advanced Solid Tumors - CT791

NoMonash Health
Haematology

Treatt: A double blind, randomised controlled trial evaluating the safety and efficacy of tranexamic acid in patients with haematological malignancies with severe thrombocytopenia.

NoPeter MacCallum Cancer Centre
Lung

CA209-227: An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab plus Ipilimumab, versus platinum doublet chemotherapy in Subjects with Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC). CT774

NoMonash Health
Haematology

54767414MMY3008: A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High Dose Therapy. CT756

NoWestern Health
Other

RAP-CLT-15-010: A Prospective Observational Trial Evaluating Outcomes of FoundationOne®-Directed Matched Targeted Therapy in Patients with Cancer of Unknown Primary (CUP)

NoPeter MacCallum Cancer Centre
Palliative Care

CADET: CAncer DExamethasone Trial (CADET) Part 1: A multi-centre single-arm, feasibility study of oral dexamethasone in the management of cancer-related pain. 026/15

NoRoyal Melbourne Hospital
Lung

CLDK378A2X01B- An open-label, multi-center, Phase IV, roll-over study in patients with ALK positive malignancies who have completed a prior Novartis-sponsored ceritinib (LDK378) study and are judged by the investigator to benefit from continued treatment with ceritinib. CT785

NoPeter MacCallum Cancer Centre
Phase 1

BGB-A317/BGB-290_Study_001: A Phase 1b, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activity of the anti-PD-1 Monoclonal Antibody BGB-A317 in combination with the PARP inhibitor BGB-290 in Subjects with Advanced Solid Tumors. CT783

NoMonash Health; Peter MacCallum Cancer Centre
Haematology

CCTL019A2205B: Long Term Follow-Up of Patients Exposed to Lentiviral- Based CD19 directed CART Cell Therapy. Juliet - CT767

NoPeter MacCallum Cancer Centre
Haematology

CCTL019B2206: A multicenter study of apheresis collection of peripheral blood mononuclear cells (PBMC) in patients with CD19 expressing malignancies who could be eligible for a CTL019 clinical research trial. Juliet - CT768

NoPeter MacCallum Cancer Centre
Haematology

CCTL019C2201: A phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Juliet - CT766

NoPeter MacCallum Cancer Centre
Gynaecology

Javelin Ovarian 200: A phase 3, multicenter, randomized, open-label study of avelumab* (MSB0010718C) alone or in combination with pegylated lipsomal doxorubicin versus pegylated liposomal doxorubicin alone in patients with platinum-resistant/refractory ovarian cancer. B9991009 - CT779

NoCabrini Institute
Haematology

ACE-CL-006: A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia. CT784

NoPeter MacCallum Cancer Centre
Uro-Oncology

ENZARAD: Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised, prostate cancer. ANZUP 1303- NC115

NoWestern Health
Haematology

A Phase 1b/2 Study to Assess Safety, Tolerability and Antitumor Activity of the Combination of BGB-3111 with Obinutuzumab in Subjects with B-Cell Lymphoid Malignancies. BGB-3111_GA101_Study_001 - CT775

NoBarwon Health; Cabrini Health
Breast

ZMC-ARX788-101: A Phase 1, Multicenter, Open-label, Multiple Dose-escalation Study of ARX788, Intravenously Administered as a Single Agent in Subjects with Advanced Breast Cancer with Multiple Levels of HER2 Expression.  CT782

NoMonash Health
Other

PLX108-10: A Double-blind, Randomized, Placebo-controlled Phase 3 Study of Orally Administered PLX3397 in Subjects with Pigmented Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath. CT754

NoPeter MacCallum Cancer Centre
Phase 1

CIDH305X2101: A Phase I study of IDH305 in patients with advanced malignancies that harbor IDH1R132 mutations. CT757

NoRoyal Melbourne Hospital
Haematology

CAMMERAY: An Australasian, phase II, multicentre, randomised, study investigating safety and efficacy for dose reduced fludarabine, cyclophosphamide and i.v. obinutuzumab (G-FC3) versus oral chlorambucil and i.v. obinutuzumab (G-Clb) in previously untreated, comorbid (CIRS score ≥6), elderly (≥65 years old) patients with chronic lymphocytic leukaemia (CLL). CLL07 - NC116

NoWestern Health
Uro-Oncology

Armor3-SV: A phase 3, randomized, open label, multicenter, controlled study of galeterone compared to enzalutamide in men expressing androgen receptor splice variant-7 mRNA (AR-V7) metastatic (M1) castrate resistant prostate cancer (CRPC). TOK-200-15 - CT761

NoMonash Health; Peter MacCallum Cancer Centre
Haematology

A Phase 1b Study of ABT-199 (GDC-0199) in Combination with Azacitidine or Decitabine in Treatment Naïve Subjects with Acute Myelogenous Leukemia Who Are ≥ 65 Years of Age and Who Are Not Eligible for Standard Induction Therapy. M14-358 - CT750

NoPeter MacCallum Cancer Centre
Lung

ARCTIC: A Phase III, Open label, Randomised, Multi-centre, International Study of MEDI4736, versus Standard of Care in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV) Who Have Received at Least Two Prior Systemic Treatment Regimens Including One Platinum-based Chemotherapy Regimen and Do Not Have Known EGFR TK Activating Mutations or ALK Rearrangements. D4191C00004 - CT742

NoBallarat Health, Bendigo Health
Brain

VERTU: A Randomised Phase II study of veliparib + radiotherapy (RT) with adjuvant temozolomide (TMZ) + veliparib versus standard RT + TMZ followed by TMZ in patients with newly diagnosed glioblastoma (GBM) with unmethylated O (6)-methylguanine-DNA methyltransferase (MGMT). NC111 - COGNO 14/01

NoRoyal Melbourne Hospital
Lung

Mystic: A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination with Tremelimumab Therapy or MEDI4736 Monotherapy Versus Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer. D419AC00001 - CT773

NoRoyal Melbourne Hospital
Uro-Oncology

Top Gear: A randomised phase II/III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer. TROG 08.08

NoWestern Health
Phase 1

A Phase Ib, open-label, dose-escalation study of the safety and pharmacokinetics of MOXR0916 and MPDL3280A in patients with locally advanced or metastatic solid tumors. GO29674 - CT769

NoPeter MacCallum Cancer Centre
Lung

Javelin Lung 100: A Phase III open-label, multicenter trial of avelumab(MSB0010718C) versus docetaxel in subjects with non-small cell lung cancer that has progressed after a platinum-containing doublet. EMR100070-004 - CT758

NoBallarat Health; Royal Melbourne Hospital
Lung

A Phase 2 Study of TH-4000 in Patients with EGFR-Mutant, T790M-Negative, Advanced Non-Small Cell Lung Cancer Progressing on an EGFR Tyrosine Kinase Inhibitor. TH-CR-601 - CT762

NoPeter MacCallum Cancer Centre
Other

TH-CR-602: A Phase 2 Study of TH-4000 in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin. CT763

NoPeter MacCallum Cancer Centre
Lung

B7391003: A Phase 3 randomized, double blind study of PF-06439535 plus Paclitaxel-Carboplatin and Bevacizumab plus Paclitaxel-Carboplatin for the first-line treatment of patients with advanced non-squamous non-small cell lung cancer. CT760

NoWestern Health
Breast

Keynote 086: A Phase II Study of Pembrolizumab as Monotherapy for Metastatic Triple-Negative Breast Cancer (mTNBC).

NoPeter MacCallum Cancer Centre
Uro-Oncology

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab plus Docetaxel Versus Placebo plus Docetaxel in Patients with Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based Therapy. I4T-MC-JVDC - CT751

NoWestern Health
Breast

PIKNIC: A Phase II exploratory, open-label, single arm study of BYL719 monotherapy, a selective PI3K alpha inhibitor, in adult patients with advanced breast cancer progressing after first line therapy. CT772 - CBYL719XAU01T

NoPeter MacCallum Cancer Centre
Haematology

NMP: A phase I, open label dose escalation trial of orally administered N-methyl-pyrrolidone (NMP) in patients with relapsed or refractory myeloma - NC110

NoRoyal Melbourne Hospital; Peter MacCallum Cancer Centre
Gastrointestinal

DYNAMIC: Circulating Tumour DNA to Guide Adjuvant Chemotherapy Decisions in Stage II Colon Cancer. WEHI-ctDNA-04 - NC105

NoRoyal Melbourne Hospital, Western Health
Breast

M-BEP: A Phase 1b Study of Bcl-2 inhibition with ABT-199 in combination with Tamoxifen in Metastatic ER-Positive Breast Cancer.

NoRoyal Melbourne Hospital
Lung

BR.31: A phase III prospective double blind placebo controlled randomized study of Adjuvant Medi4736 in completely resected non-small cell lung cancer. NC109

NoRoyal Melbourne Hospital
Uro-Oncology

BL.12. A multicentre randomized phase II trial comparing NAB-paclitaxel to paclitaxel in patients with advanced urothelial cancer progressing on or after a platinum containing regimen. NC108

NoWestern Health
Uro-Oncology

Embark: A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men With High-Risk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy. MDV3100-13 - CT747

NoWestern Health
Other

A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. MK3475-048 - CT755

NoPeter MacCallum Cancer Centre
Breast

A Phase III, Multicenter, Randomized, Placebo-controlled study of MPDL3280A (anti-PD-L1 Antibody) in combination with Nab-Paclitaxel for patients with previously untreated metastatic triple-negative breast cancer. WO29522 - CT732

NoWestern Health, Peter MacCallum Cancer Centre
Lung

GO29437: A Phase III, Open-Label, Multicenter, Randomized study evaluating the efficacy and safety of MPDL3280A (anti PD-L1 antibody) in combination with Carboplatin + Paclitaxel or MPDL3280A in combination with carboplatin + nab-paclitaxel versus carboplatin + nab-paclitaxel in chemotherapy naive patients with stage IV squamous non-smell cell lung cancer. CT743. 

NoWestern Health, Alfred Health, Cabrini Health
Melanoma

Keynote 054: Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double-blind Phase 3 trial of the EORTC Melanoma Group. MK-3475-054 - CT764.

NoPeter MacCallum Cancer Centre, Alfred Health
Other

BGB-A317_Study_001: A Phase 1, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activities of the anti-PD-1 Monoclonal Antibody BGB-A317 in Subjects with Advanced Tumors. CT745

NoRoyal Melbourne Hospital, Monash Health, Peter MacCallum Cancer Centre, Cabrini Health
Breast

Penelope B: Phase III study evaluating Palbociclib (PD-0332991), a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor in patients with hormone-receptor-positive, HER2-normal primary breast cancer with high relapse risk after neoadjuvant chemotherapy. GBG78 - NC100

NoWestern Health
Other

PUMA-NER-5201: An open-label, phase 2 study of Neratinib in patients with solid tumors with somatic human epidermal growth factor receptor (EGFR, HER2, HER3) mutations or EGFR gene amplification. CT733

NoPeter MacCallum Cancer Centre
Lung

GO29436: A Phase III, open-label, randomized study of MPDL3280A (Anti-PD-L1 Antibody) in combinatino with Carboplatin+ Paclitaxel with or without Bevacizumab compared with Carboplatin+Paclitaxel+Bevacizumab in chemotherapy-naive patients with stage IV non-squamous non-small cell lung cancer. CT741

NoWestern Health, Alfred Health
Other

EWING 2008: A Phase 3, Open Label, Multi-Centre, Randomised Controlled International Study in Ewing Sarcomas. EE08 - NC92

 

 

NoPeter MacCallum Cancer Centre
Gastrointestinal

Yosemite: A 3-Arm Phase 2 Double-Blind Randomized StudY of Gemcitabine, Abraxane® Plus PlacebO versuS GEMcitabIne, Abraxane® plus 1 or 2 TruncatEd Courses of Demcizumab in Subjects with 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma. M18-006. CT731

NoMonash Health, Western Health
Haematology

E7438-G000-101: An Open-Label, Multicenter, Phase 1/2 Study of E7438 (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B cell Lymphomas. CT736

NoPeter MacCallum Cancer Centre
Melanoma

CC-90003-ST-001. Phase 1A multicenter, open-label safety, tolerability and pharmacokinetic study of CC-90003, a selective extracellular signal-regulated kinase (ERK) inhibitor, in subjects with locally-advanced or metastatic, relapsed, or refractory BRAFV600 or RAS-mutated malignancies. CT735

NoPeter MacCallum Cancer Centre
Haematology

Alcyone: A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination with VMP(D-VMP), in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High-dose Therapy.  - CT738

NoBarwon Health
Gastrointestinal

NabNec: A Feasibility Study Of NAB-Paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas. NC106

NoRoyal Melbourne Hospital, Barwon Health
Haematology

Scramble: Chemotherapy followed by infusion of partially HLA matched unrelated donor cells for patients with AML who are ineligible for stem cell transplantation. NC104

NoRoyal Melbourne Hospital
Other

Exelixis: A Randomized, Double-blind Study To Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients. XL184-401 - CT720

NoRoyal Melbourne Hospital; Austin Health
Haematology

AIM Study: A Phase 2 Study of ABT-199 in Combination with Ibrutinib in the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma. AIM. NC101

NoPeter MacCallum Cancer Centre, Royal Melbourne Hospital
Breast

A phase III, double-blind, placebo-controlled, randomized study of taselisib plus Fulvestrant versus placebo plus Fulvestrant in postmenopausal women with estrogen receptor-positive and HER2-negative locally advanced or metastatic breast cancer who have disease recurrence or progression during or after aromatase inhibitor therapy. GO29058. CT714

NoWestern Health
Breast

Olympia: A randomised, double-blind, parallel group , placebo-controlled multi-centre Phase II study to assess the efficacy and safety of Olaparib versus placebo as adjuvant treatment in patient with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neo-adjuvant or adjuvant chemotherapy. D081CC00006. NC

NoPeter MacCallum Cancer Centre
Lung

Flaura: A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer. CT709

NoMonash Health
Lung

Command: A Phase II Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects with Malignant Pleural Mesothelioma. VS-6063-202. CT727

NoPeninsula Oncology Centre
Haematology

TCZ Tocilizumab: A phase III randomized study of humanized anti-IL-6 receptor antibody Tocilizumab (TCZ) to prevent development of acute graft versus host disease (GVHD) post HLA-matched allogeneic haematopoietic progenitor cell transplantation (HPCT). NC96

NoRoyal Melbourne Hospital
Haematology

ROBUST: Phase 3 randomized, double-blind, placebo controlled, multicenter study to compare the efficacy and safety of Lenalidomide (CC-5013) plus R-CHOP chemotherapy (R2-CHOP) versus placebo plus r-chop chemotherapy in subjects with previously untreated activated b-cell type diffuse large B-cell Lymphoma. CC-5013-DLC-002. CT721

NoRoyal Melbourne Hospital, Barwon Health, Bendigo Health, Border Medical Oncology, St Vincent's Health Melbourne
Breast

PANACEA: A phase Ib/II trial evaluating the efficacy of MK-3475 and trastuzumab in patients with trastuzumab-resistant, HER2-positive metastatic breast cancers. IBCSG 45-13/BIG 4-13. NC98

NoPeter MacCallum Cancer Centre
Uro-Oncology

ES414-401: A phase 1 study of ES414 in patients with metastatic castration-resistant prostate cancer. CT717

NoRoyal Melbourne Hospital, Peter MacCallum Cancer Centre
Haematology

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hematopoietic Cell Transplant (HCT) Recipients with Respiratory Syncytial Virus (RSV) Infection of the Upper Respiratory Tract. GS-US-218-0108. CT719

NoRoyal Melbourne Hospital
Lung

PACIFIC: A Phase III, Randomised, Double-blind, Placebo-controlled, Multi-centre, International Study of MEDI4736 as Sequential Therapy in Patients with Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) who have not progressed following definitive, platinum-based, concurrent Chemo-radiation Therapy. D4191C00001. CT723

NoPort Macquarie Base Hospital, Monash Health
Gastrointestinal

Brighter: A phase III randomized, double-blind, placebo-controlled clinical trial of BBI608 plus weekly Paclitaxel vs Placebo plus weekly Paclitaxel in adult patients with advanced, previously treated gastric and gastro-esophageal junction adenocarcinoma. BBI608-336. CT697

NoRoyal Melbourne Hospital, Western Health, Monash Health, Bendigo Health
Melanoma

ABC Trial: A phase II study of nivolumab and nivolumab combined with ipilimumab in patients with melanoma brain metastases. CA209-170. NC95

NoPeter MacCallum Cancer Centre
Uro-Oncology

BCG+MMC: Adding Mitomycin C to BCG as adjuvant intravesical therapy for high risk, non muscle invasive bladder cancer: a randomised phase 3 trial. ANZUP 1301. NC87

NoWestern Health
Haematology

Phase I dose-escalation study of the orally administered selective Bcl-2 inhibitor S 055746 as monotherapy for the treatment of patients with Acute Myeloid Leukaemia (AML) or high or very high risk Myelodysplastic Syndrome (MDS). CL1-055746-002. CT700

NoRoyal Melbourne Hospital
Melanoma

A Phase 1b/2a Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 232 Combined with Trametinib and Dabrafenib or Trametinib in Adult Subjects with Metastatic Cutaneous Melanoma. 20120238. CT715

NoPeter MacCallum Cancer Centre
Haematology

A phase I/II open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in subjects with relapsed, refractory hematologic malignancies. BET116183. CT711

NoPeter MacCallum Cancer Centre
Melanoma

TVEC: A Phase 1b/2, Multicenter, Open-label Trial of Talimogene Laherparepvec in Combination With MK-3475 for Treatment of Previously Untreated, Unresected, Stage IIIB to IVM1c Melanoma. 20110265. CT682

NoAustin Health, Peter MacCallum Cancer Centre, Alfred Health
Phase 1

A Phase I, open-label, dose-escalation study of the safety and pharmacokinetics of MOXR0916 administered intravenously as a single agent to patients with locally advanced or metastatic solid tumours. GO29313. CT704

NoPeter MacCallum Cancer Centre, Austin Health
Haematology

PCYC-1127-CA: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ibrutinib or Placebo in Combination With Rituximab in Subjects with Previously Treated Waldenstroms Macroglobulinemia. CT684

NoPeter MacCallum Cancer Centre
Gynaecology

LY2228820: A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Study of LY2228820, a p38 MAPK Inhibitor, plus Gemcitabine and Carboplatin versus Gemcitabine and Carboplatin for Women with Platinum-Sensitive Ovarian Cancer. I1D-MC-JIAE(a). CT531

NoThe Women's
Gastrointestinal

Circulating Tumour DNA as a Marker of Residual Cancer and Benefit from Adjuvant Chemotherapy in Stage III Colon Cancer. WEHI-ctDNA-05. NC97

NoWestern Health, Royal Melbourne Hospital
Phase 1

Octopus: A Phase Ib study of the safety and pharmacology of MPDL3280A administered with Cobimetinib in patients with locally advanced or metastatic solid tumors. GP28363. CT672

NoRoyal Melbourne Hospital; Peter MacCallum Cancer Centre
Breast

SOLACE: A phase I study of Olaparib, a poly ADP-ribose polymerase-1 (PARP) inhibitor, in combination with metronomic cyclophosphamide in patients with metastatic BRCA-associated breast cancer, triple negative breast cancer or serous ovarian cancer. ANZ1103. NC91

NoRoyal Melbourne Hospital
Haematology

MURANO: A multi-center, phase III, open-label, randomised study in relapsed/refractory patients with chronic lymphocytic leukemia to evaluate the benefit of GDC-0199 (ABT-199) plus Rituximab compared with Bendamustine plus Rituximab. GO28667. CT670

NoRoyal Melbourne Hospital
Haematology

R3ACT: Therapeutic infusion of most closely HLA-matched third party donor-derived virus-specific cytotoxic T-lymphocytes in patients with active viral reactivation post-allogeneic stem cell transplantation (R3ACT). NC85

NoRoyal Melbourne Hospital
Breast

BRCA-D: A pre-operative window study evaluating the biological effects of the RANK-Ligand(RANKL) inhibitor Denosumab on normal breast tissue from BRCA1 and BRCA2.

NoRoyal Melbourne Hospital
Haematology

ECHELON-2: A randomised, double-blind, placebo-controlled, phase 3 study of Brentuximab Vedotin and CHP (A+CHP) versus CHOP in the front-line treatment of patients with CD30-positive mature T-cell lymphomas. SGN35-014. CT654

NoWestern Health
Uro-Oncology

BAY 88-8223/15396: A phase III randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with abiraterone acetate and prednisone/prednisolone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve subjects with bone predominant metastatic castration-resistant prostate cancer (CRPC). CT694

NoPeter MacCallum Cancer Centre, Monash Health
Haematology

BGB-3111-AU-003: A Phase IA, Open-Label, Multiple-Dose, Dose Escalation Study to Investigate the Safety and Pharmacokinetics of the BTK Inhibitor BGB-3111 in Subjects with Indolent B-Cell Lymphoid Malignancies. CT691

NoPeter MacCallum Cancer Centre, Royal Melbourne Hospital
Breast

Pre-Treat: A window study of short-term Pre-operative Treatment with tamoxifen or letrozole in estrogen receptor (ER) positive breast cancer. NC88

NoRoyal Melbourne Hospital
Phase 1

TPU-TAS-120-101: A dose finding Phase 1 study of TAS-120 in patients with advanced solid tumours with or without fibroblast growth factor/receptor FGF/FGFR-related abnormalities followed by a Phase 2 study in patients with advanced solid tumors or multiple myeloma with FGF/FGFR-related abnormalities. CT680

NoRoyal Melbourne Hospital
Haematology

GO27878: A phase Ib/II, open-label study evaluating the safety and pharmacokinetics of GDC-0199 (ABT-199) in combination with Rituximab (R) or Obinutuzumab (G) plus Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (CHOP) in patients with B-cell Non-Hodgkins Lymphoma (NHL) AND DLBCL. CT690

NoRoyal Melbourne Hospital, Peter MacCallum Cancer Centre
Other

The Rare Disease Registry Program (including but not limited to, Gaucher, Fabry, MPS I, and Pompe diseases) is a longitudinal, international, observational program that tracks outcomes of routine clinical practice for patients with these rare diseases. NC86

NoRoyal Melbourne Hospital
Haematology

A Study of IPI-145 and Ofatumumab in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Previously Enrolled in Study IPI-145-07. IPI-145-12. CT669

NoPeter MacCallum Cancer Centre
Lung

EViCT: A Phase I/II Trial of the combination of BRAF and EGFR inhibition in BRAF V600E mutant metastatic colorectal, advanced or metastatic lung adenocarcinoma and other cancers: The EViCT (Erlotinib and Vemurafenib In Combination Trial) Study. ML28737. 2014.019. NC68

NoPeter MacCallum Cancer Centre, Royal Melbourne Hospital, Monash Health, Austin Health, Western Health
Gastrointestinal

Circulating Tumour DNA as a Marker of Prognosis and Chemotherapy Benefit in Patients with Metastatic Colorectal Cancer. WEHI-ctDNA-03. NC89

NoRoyal Melbourne Hospital, Western Health
Breast

The METRIC Study: A Randomised Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer. CT651

NoAustin Health, Western Health
Haematology

A Phase 2 Study of patients treated for relapsed Follicular Lymphoma: with Revlimid® consolidation added to Rituximab maintenance therapy in those remaining PET positive. NHL26. NC67

NoWestern Health; Royal Melbourne Hospital
Breast

PALOMA-3: Multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of Fulvestrant (Faslodex) with or without PD-0332991 (Palbociclib)+/-Goserelin in women with hormone receptor-positive, HER2-negative metastatic breast cancer whose disease progressed after prior endocrine therapy. CT646

NoCabrini, Western Health
Lung

Phase 1/2 study of PF-06463922 (an ALK/ROS1 Tyrosine Kinase inhibitor) in patients with advanced non-small cell lung cancer harboring specific molecular alterations. CT661

NoPeter MacCallum Cancer Centre
Breast

A pre-operative window study evaluating Denosumab, a RANK-ligand (RANKL) inhibitor and its biological effects in young pre-menopausal women diagnosed with early (D BEYOND).

NoRoyal Melbourne Hospital
Gynaecology

A Phase II study to evaluate the safety and potential palliative benefit of intraperitoneal bevacizumab in patients with symptomatic ascites due to advanced chemotherapy resistant ovarian cancer. NC59

NoPeter MacCallum Cancer Centre
Haematology

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma. CT613

NoPeter MacCallum Cancer Centre
Uro-Oncology

Phase 3 Accelerated BEP Trial: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours. ANZUP 1302. NC64

NoPeter MacCallum Centre; Western Health
Haematology

PRISM: A Phase 1B Dose Escalation Study to Investigate the Safety, Tolerability and Preliminary Efficacy for the Combination of Dasatinib (BMS-354825) plus Nivolumab (BMS-936558) in Patients with Chronic Myeloid Leukemia (CML). CT629

NoRoyal Melbourne Hospital
Breast

A phase Ib/II, multicenter, study of LEE011 in combination with letrozole and LEE011 with letrozole and BYL719 in adult patients with advanced HR+ breast cancer. CT618

NoRoyal Melbourne Hospital
Uro-Oncology

SPARTAN: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer. CT602

NoRoyal Melbourne Hospital
Phase 1

A Phase IA/IB, Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety and Pharmacokinetics of the B-RAF Inhibitor BGB-283 in Subjects with Solid Tumours. CT634

NoPeter MacCallum Cancer Centre, Royal Melbourne Hospital, Cabrini Health
Gynaecology

A Phase 2, Open-Label Study of Rucaparib in Patients with Platinum Sensitive, Relapsed, High-Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. CT609

NoRoyal Melbourne Hospital
Uro-Oncology

PROSPER: A Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer (MDV3100-14). CT622

NoMonash Health, Peter MacCallum Cancer Centre, Western Health
Gastrointestinal

Circulating Tumour DNA as a Biomarker Pancreatic Cancer. NC55

NoRoyal Melbourne Hospital, Western Health
Lung

A Phase 2, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects with Unresectable Pleural or Peritoneal Malignant Mesothelioma. D4880C00003. CT594

NoAustin Health, Monash Health
Haematology

A Phase 1, Open-Label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Intravenously Administered CX-5461 in Patients with Advanced Haematologic Malignancies. NC52

NoPeter MacCallum Cancer Centre
Gastrointestinal

A Randomized, Phase III, Multicenter, Double-blind, Placebo Controlled study evalautaing the efficacy and safety of Onartuzumab (MetMab) in combination with 5-Flurouracil, Folinic Acid, and Oxaliplatin (mFOLFOX6) in patients with Metastic HER2-Negative, Met-postiive Gastroesophegal Cancer. CT564

NoMonash Medical Centre
Gastrointestinal

TROG 12.01: A Randomised Trial of Weekly Cetuximab and Radiation versus Weekly Cisplatin and Radiation in Good Prognosis Locoregionally Advanced HPV-Associated Oropharyngeal Squamous Cell Carcinoma. (HPV OROPHARYNX). NC57

 

NoPeter MacCallum Cancer Centre
Melanoma

An Open Label, Phase I Study To Evaluate The Impact Of Severe Hepatic Impairment On The Pharmacokinetics And Safety Of Vemurafenib In BRAFV600 Mutation Positive Cancer Patients. CT601

NoPeninsula Oncology Centre
Lung

A Multinational, Randomized, Open-Label Phase III Study of Custirsen (TV-1011/OGX-011) In Combination With Docetaxel Versus Docetaxel As A Second-Line Treatment In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer. CT572 

NoBorder Medical Oncology, Cabrini Health
Gastrointestinal

ICE CREAM: Randomised Phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic CRC with either KRAS WT or G13D mutation. NC50

NoPeter MacCallum Cancer Centre
Haematology

AMLM18: Australasian Leukaemia and Lymphoma Group Acute Myeloid Leukaemia Registry NC51

NoMelbourne Health, Peter MacCallum Cancer Centre
Haematology

Sorafenib in combination with intensive chemotherapy for previously untreated adult FLT3-ITD positive AML: A Phase 2 randomised double-blind placebo controlled multi-centre study. ALLG AML M16. NC49

NoRoyal Melbourne Hospital, Peter MacCallum Cancer Centre
Brain

ACT IV: An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma. CT510

NoMonash Health
Haematology

The lymphoma lifestyle, environment and family study. NC43

NoPeter MacCallum Cancer Centre, Western Health
Lung

TROG 11.03: A Randomised phase III trial of high dose Palliative Radiotherapy (HDPRT) versus concurrent Chemotherapy + HDPRT (C-HDPRT) in patients with good performance status, locally advanced/small volume metastatic NSCLC not suitable for radical Chemo-radiotherapy. NC53

NoPeter MacCallum Cancer Centre
Haematology

BO21223: A multicenter, Phase III, Open-Label, randomized study in previously untreated patients with advanced indolent Non-Hodgkin’s Lymphoma evaluating the benefit of GA101 (RO5072759) plus chemotherapy compared with rituximab plus chemotherapy followed by GA101 or rituximab maintenance therapy in responders. CT489

NoSt. Vincent's Health
Haematology

CLL6 (RESIDUUM): An Australasian, Phase III, Multicentre, Randomised Trial Comparing Lenalidomide Consolidation Vs No Consolidation in Patients With Chronic Lymphocytic Leukemia and Residual Disease Following Induction Chemotherapy. NC20

NoAusitn Hospital, Western Hospital, Royal Melbourne Hospital
Gynaecology

OUTBACK: A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally-advanced cervical cancer compared to chemoradiation alone. NC19

NoPeter MacCallum Cancer Centre
Haematology

Double Think: Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry. M07-001. CT373

NoRoyal Melbourne Hospital
Phase 1

Phase 1 safety, pharmacokinetic and pharmacodynamic study of PF-02341066, a c-met/hgfr selective tyrosine kinase inhibitor, administered orally to patients with advanced cancer. CT316

NoPeter MacCallum Cancer Centre
Back to Top